Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
248 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2014', provides an overview of the Recurrent Glioblastoma Multiforme (GBM)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Recurrent Glioblastoma Multiforme (GBM) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Recurrent Glioblastoma Multiforme (GBM) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Recurrent Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Recurrent Glioblastoma Multiforme (GBM) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Recurrent Glioblastoma Multiforme (GBM) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Recurrent Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 7 Global Markets Direct Report Coverage 7 Recurrent Glioblastoma Multiforme (GBM) Overview 8 Therapeutics Development 9 Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) - Overview 9 Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis 10 Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies 11 Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes 13 Recurrent Glioblastoma Multiforme (GBM) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Recurrent Glioblastoma Multiforme (GBM) - Products under Development by Companies 17 Recurrent Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes 20 Recurrent Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development 21 Agenus, Inc. 21 Amgen Inc. 22 AngioChem Inc. 23 Apogenix GmbH 24 AstraZeneca PLC 25 Axelar AB 26 Boehringer Ingelheim GmbH 27 Celldex Therapeutics, Inc. 28 Eisai Co., Ltd. 29 Eli Lilly and Company 30 EnGeneIC Ltd 31 ERC Belgium SA 32 Genentech, Inc. 33 GenSpera, Inc. 34 GlaxoSmithKline plc 35 GW Pharmaceuticals plc 36 ImmunoCellular Therapeutics, Ltd. 37 Karyopharm Therapeutics, Inc. 38 Novartis AG 39 OncoEthix SA 40 Ono Pharmaceutical Co., Ltd. 41 Pfizer Inc. 42 Sangamo BioSciences, Inc. 43 Spectrum Pharmaceuticals, Inc. 44 Threshold Pharmaceuticals, Inc. 45 Tocagen Inc. 46 Vascular Biogenics Ltd. 47 Virttu Biologics Limited 48 ZIOPHARM Oncology, Inc. 49 Recurrent Glioblastoma Multiforme (GBM) - Therapeutics Assessment 50 Assessment by Monotherapy Products 50 Assessment by Combination Products 51 Assessment by Target 52 Assessment by Mechanism of Action 56 Assessment by Route of Administration 59 Assessment by Molecule Type 61 Drug Profiles 63 (GWP-42002 + GWP-42003) - Drug Profile 63 Ad-RTS-IL-12 - Drug Profile 64 afatinib - Drug Profile 66 AMG-595 - Drug Profile 70 ANG-1005 - Drug Profile 72 APG-101 - Drug Profile 74 axitinib - Drug Profile 76 AXL-1717 - Drug Profile 79 AZD-7451 - Drug Profile 81 BGJ-398 - Drug Profile 82 bosutinib - Drug Profile 83 buparlisib hydrochloride - Drug Profile 85 dacomitinib - Drug Profile 89 Dendritic Cell Therapy for Recurrent Glioblastoma Multiforme - Drug Profile 91 DNX-2401 - Drug Profile 92 dovitinib lactate - Drug Profile 94 doxorubicin - Drug Profile 97 ERC-1671 - Drug Profile 98 erismodegib - Drug Profile 100 evofosfamide - Drug Profile 103 G-200 - Drug Profile 110 galunisertib - Drug Profile 112 GDC-0084 - Drug Profile 114 golvatinib + lenvatinib - Drug Profile 115 HSV-1716 - Drug Profile 117 ICT-121 - Drug Profile 119 MDNA-55 - Drug Profile 120 mipsagargin - Drug Profile 121 nabiximols - Drug Profile 123 nivolumab (recombinant) - Drug Profile 126 Oncolytic Virus to Target IL-12 for Oncology - Drug Profile 131 ortataxel - Drug Profile 132 OS-2966 - Drug Profile 133 OTX-015 - Drug Profile 134 pazopanib hydrochloride - Drug Profile 136 rilotumumab - Drug Profile 141 rindopepimut - Drug Profile 143 SB-313 - Drug Profile 145 selinexor - Drug Profile 146 TPI-287 - Drug Profile 149 trebananib - Drug Profile 151 Vaccine to Target Carcinoembryonic Antigen for Oncology - Drug Profile 154 vandetanib - Drug Profile 155 VB-111 - Drug Profile 161 vocimagene amiretrorepvec + flucytosine ER - Drug Profile 162 Recurrent Glioblastoma Multiforme (GBM) - Recent Pipeline Updates 164 Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects 235 Recurrent Glioblastoma Multiforme (GBM) - Discontinued Products 236 Recurrent Glioblastoma Multiforme (GBM) - Product Development Milestones 237 Featured News & Press Releases 237 Appendix 244 Methodology 244 Coverage 244 Secondary Research 244 Primary Research 244 Expert Panel Validation 244 Contact Us 245 Disclaimer 245
List of Tables Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM), H2 2014 12 Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2014 13 Number of Products under Development by Companies, H2 2014 14 Number of Products under Investigation by Universities/Institutes, H2 2014 16 Comparative Analysis by Late Stage Development, H2 2014 17 Comparative Analysis by Clinical Stage Development, H2 2014 18 Comparative Analysis by Early Stage Development, H2 2014 19 Products under Development by Companies, H2 2014 20 Products under Development by Companies, H2 2014 (Contd..1) 21 Products under Development by Companies, H2 2014 (Contd..2) 22 Products under Investigation by Universities/Institutes, H2 2014 23 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Agenus, Inc., H2 2014 24 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc., H2 2014 25 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc., H2 2014 26 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Apogenix GmbH, H2 2014 27 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by AstraZeneca PLC, H2 2014 28 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Axelar AB, H2 2014 29 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H2 2014 30 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics, Inc., H2 2014 31 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co., Ltd., H2 2014 32 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H2 2014 33 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H2 2014 34 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H2 2014 35 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Genentech, Inc., H2 2014 36 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by GenSpera, Inc., H2 2014 37 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline plc, H2 2014 38 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals plc, H2 2014 39 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2014 40 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 41 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H2 2014 42 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by OncoEthix SA, H2 2014 43 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 44 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc., H2 2014 45 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Sangamo BioSciences, Inc., H2 2014 46 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 47 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2014 48 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc., H2 2014 49 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd., H2 2014 50 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Virttu Biologics Limited, H2 2014 51 Recurrent Glioblastoma Multiforme (GBM) - Pipeline by ZIOPHARM Oncology, Inc., H2 2014 52 Assessment by Monotherapy Products, H2 2014 53 Assessment by Combination Products, H2 2014 54 Number of Products by Stage and Target, H2 2014 56 Number of Products by Stage and Mechanism of Action, H2 2014 60 Number of Products by Stage and Route of Administration, H2 2014 63 Number of Products by Stage and Molecule Type, H2 2014 65 Recurrent Glioblastoma Multiforme (GBM) Therapeutics - Recent Pipeline Updates, H2 2014 167 Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2014 238 Recurrent Glioblastoma Multiforme (GBM) - Discontinued Products, H2 2014 239
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
